Zepbound's 2023 launch carried a suicidal ideation warning that lasted two years
Zepbound's weight-management label carried a suicidal ideation warning for just over two years after its 2023 launch, and the FDA record does not explain the change.
The FDA approved tirzepatide as Zepbound for chronic weight management on Nov. 8, 2023, and the label that came with it carried a warning for suicidal behavior and ideation, matching warnings already used on the weight-management drugs Saxenda and Wegovy. The warning stayed on the Zepbound label for just over two years.
Zepbound is the weight-management form of Eli Lilly's tirzepatide, which acts on the GIP and GLP-1 receptors and is also sold as Mounjaro for type 2 diabetes [1]. The FDA lists Zepbound under application number NDA 217806 [2].
The FDA's record of safety-related labeling changes for Zepbound shows what has been added since. A change approved Sept. 25, 2025 covered acute kidney injury caused by volume depletion, telling prescribers to monitor kidney function in patients who report reactions that can lead to fluid loss, especially when the drug is started or the dose is raised. That same update added acute renal failure and worsening chronic renal failure, sometimes requiring dialysis, to the postmarketing list [2]. Changes approved Jan. 7 and Jan. 20, 2026 covered storage and injection instructions and added a warning that a Zepbound KwikPen must never be shared between patients, even if the needle is changed, because of the risk of blood-borne infections [2].
A Feb. 25, 2026 update added rates of severe gastrointestinal reactions from two Zepbound weight-reduction trials: 1.7% at 5 mg, 2.5% at 10 mg and 3.1% at 15 mg, compared with 1% for placebo. It also states that Zepbound is not recommended in patients with severe gastroparesis, and adds hemorrhagic and necrotizing pancreatitis, sometimes resulting in death, ileus, intestinal obstruction, and severe constipation including fecal impaction to the postmarketing side-effect list [2].
On pancreatitis, that update reports 14 confirmed cases in 13 tirzepatide-treated patients (0.23 patients per 100 years of exposure) against 3 cases in 3 comparator patients (0.11 per 100) in trials for a different indication. In the two weight-reduction trials, 0.2% of Zepbound-treated patients had confirmed acute pancreatitis (0.14 per 100 years) versus 0.2% of placebo patients (0.15 per 100) [2]. In Zepbound trials for obstructive sleep apnea, the exposure-adjusted rate was 0.84 per 100 years for Zepbound and 0 for placebo [2]. A Sept. 25, 2025 update added lactation data: after a single 5 mg dose in 11 healthy breastfeeding women, tirzepatide was undetectable in 164 of 171 breast-milk samples, with a detection limit of 4 ng/mL [2].
The FDA's listing of safety-related labeling changes for Zepbound does not include an entry describing the removal of the suicidal behavior and ideation warning, and the agency's reasoning for the change has not been reported.
Why it matters for patients
Label warnings shape what a patient is told at the pharmacy counter and what a clinician raises at a visit. Someone who started Zepbound in 2024 received a Medication Guide that named suicidal thoughts as a possible serious side effect; the guide packaged with the drug today may read differently.
The side-effect list has grown in other ways. Severe gastrointestinal reactions, acute kidney injury from fluid loss, and pancreatitis now appear on it, so the symptoms patients are told to watch for form a longer list than at launch [2]. The trial numbers show how often most of these events occurred, and for the weight-management population they were uncommon: severe gastrointestinal reactions reached 3.1% at the highest dose studied, and confirmed pancreatitis occurred in 0.2% of Zepbound patients in the weight-reduction trials, the same share as placebo [2].
What has not been reported is why the suicidal ideation warning came off, whether regulators reviewed new data on suicidal thoughts with tirzepatide, or whether the labels for Wegovy and Saxenda changed as well.
What happens next
The Zepbound label is still being revised; the most recent safety-related change listed for it is dated Feb. 25, 2026 [2]. Tirzepatide's use in children has also been under review: FDA reviewers completed their assessment of a supplemental application for Mounjaro as an add-on to diet and exercise in patients 10 years and older with type 2 diabetes on Nov. 26, 2025, ahead of a Dec. 19, 2025 goal date, and recommended approval [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.